Ratings VITA 34 AG Berne S.E.

Equities

V3V

DE000A0BL849

Delayed Berne S.E. Other stock markets			5-day change	1st Jan Change
- ^CHF	-.--%		-.--%	-.--%

01/06	VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Sales forecast by analysts have been recently revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
VITA 34 AG	-.--%	84.42M		-
HCA HEALTHCARE, INC.	+16.97%	84.15B		C+
CVS HEALTH CORPORATION	-25.62%	74.14B		B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.35%	26.77B		C+
LABCORP HOLDINGS INC.	-10.69%	17.15B		B
FRESENIUS SE & CO. KGAA	+0.82%	16.83B		A-
QUEST DIAGNOSTICS INCORPORATED	-0.70%	15.21B		A-
NATERA, INC.	+71.44%	13.3B		C-
TENET HEALTHCARE CORPORATION	+76.66%	12.99B		C+
PURE HEALTH HOLDING	-25.61%	12.79B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes